<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To investigate the effect of ipragliflozin on the pharmacokinetics of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> or <z:chebi fb="0" ids="5383">glimepiride</z:chebi> and vice versa in healthy subjects </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Three trials with an open-label, randomized, two-way crossover design were conducted in healthy subjects </plain></SENT>
<SENT sid="2" pm="."><plain>Ipragliflozin 150 mg, <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> 100 mg, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> 30 mg or <z:chebi fb="0" ids="5383">glimepiride</z:chebi> 1-2 mg were administered alone or in combination </plain></SENT>
<SENT sid="3" pm="."><plain>Primary endpoints were the area under the curve from the time of dosing to infinity (AUC(inf)) and the maximum observed plasma concentration (C(max)) of each drug </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Multiple doses of ipragliflozin did not change the AUC(inf) and C(max) of a single dose of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> or <z:chebi fb="0" ids="5383">glimepiride</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> geometric mean ratios and 90% CIs for AUC(inf) and C(max) , with and without ipragliflozin, were within the predefined range of 80-125% (AUC(inf) : <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> 100.1 [96.9-103.5], <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> 101.7 [96.6-107.0], <z:chebi fb="0" ids="5383">glimepiride</z:chebi> 105.1 [101.3-109.0], and C(max) : <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> 92.4 [82.8-103.1], <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> 98.6 [87.7-110.8], <z:chebi fb="0" ids="5383">glimepiride</z:chebi> 110.0 [101.9-118.8]) </plain></SENT>
<SENT sid="6" pm="."><plain>Similarly, multiple doses of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> or <z:chebi fb="0" ids="5383">glimepiride</z:chebi> did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]) </plain></SENT>
<SENT sid="7" pm="."><plain>Ipragliflozin either alone or in combination with any of the three <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering drugs was well tolerated in healthy subjects </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Ipragliflozin did not affect the pharmacokinetics of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> or <z:chebi fb="0" ids="5383">glimepiride</z:chebi> and vice versa, suggesting that no dose-adjustments are likely to be required when ipragliflozin is given in combination with other <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering drugs in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>